The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome

Phase 4

Completed

• Conditions: Oral Health
• Interventions: Drug: 1% Betadine® PVP-I based mouth wash and gargle,; Drug: 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash; Drug: Normal saline gargle

• Registration Number: NCT03141554
• Lead Sponsor: Mundipharma Manufacturing Pte Ltd.

Brief Summary

This study determines the effects of a single dose of different antiseptic mouth washes within the oral cavity, on the composition of the oral microbiome using next generation sequencing (NGS) techniques. Twelve healthy volunteers will receive all three test products in a randomized order to compare the effects of each mouth wash.

Detailed Description

Disinfectants and oral antiseptics including PVP-I are known to kill microorganisms to a variable extent, at a variable range of time points. Microorganisms may be protected from disinfectants by production of thick masses of cells and extracellular materials, or biofilms. Moreover, antiseptics should not lead to dysbiosis after use. Dysbiosis is a negative change in the microbiome of a particular skin or mucosal region. The Human Microbiome project showed, that every area has a specific microbiota in which the human host lives with an abundance of commensal, synergistic, and potentially pathogenic microorganisms. Antiseptics with efficacy gaps and resistance may induce such dysbiosis, especially after prolonged use.

It is envisaged that twelve healthy volunteers will complete the study. Each healthy volunteer will rinse with the test product according to a developed protocol, between established wash out periods.

The ability of the test product (1% Betadine® PVP-I based mouth wash and gargle) compared to the reference products (0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (No alcohol) and Normal saline gargle) to reduce resident and transient microflora will be assessed. The mouth wash products will also be assessed for their ability to maintain and/or restore balanced microflora.

Study Timeline

• Study First Submitted: 2017-02-22
• Study First Submitted QC: 2017-05-02
• Study Start: 2017-05-05
• Study First Posted: 2017-05-05
• Primary Completion: 2017-05-19
• Study Completion: 2017-05-19
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-05
• Last Update Posted: 2017-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Male and female subjects 21 years and older,
• Not pregnant nor trying to conceive during the study period,
• Non-smoker, non-tobacco user (no chewing of tobacco or similar products),
• No systemic or topical oral antibiotic or antifungal in the past 2 months (from date of consent),
• No ongoing medication (e.g., immunosuppressive medication, no systemic or inhaled glucocorticoids),
• Prepared to use a toothpaste that does not any antimicrobials (Colgate Maximum Cavity Protection) for 2 days after providing consent and during the study,
• Prepared to refrain from using mouth washes/gargles or any other oral hygiene product for 2 days after providing consent and during the study,
• Good oral health (e.g., no visible bleeding, inflammation, oral ulcer or oral lesion, no need for dental treatment),
• Must have given written informed consent.

Exclusion Criteria

• Allergy or contraindication to any test product substance (active or excipients),
• Known hyperthyroidism,
• Consumption of alcoholic beverages 24 hours before test product administration on Day 0, Day 2, and Day 4,
• Wearing dental appliances (all types of braces, removable or fixed dentures, etc.),
• Minor ailments like cough, cold, upper respiratory tract infection(s), or oral ulcer(s),
• Unwillingness or inability to comply with the requirements of the protocol,
• Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to the screening visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Treatment Sequence Group 1	0.2% Chlor-Rinse™ Chlorhexidine based mouth wash	Treatment Sequence Group 1 = A -\> B -\> C Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm).
Treatment Sequence Group 3	0.2% Chlor-Rinse™ Chlorhexidine based mouth wash	Treatment Sequence Group 3 = C -\> A -\> B Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
Treatment Sequence Group 1	Normal saline gargle	Treatment Sequence Group 1 = A -\> B -\> C Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm).
Treatment Sequence Group 2	1% Betadine® PVP-I based mouth wash and gargle,	Treatment Sequence Group 2 = B -\> C -\> A Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
Treatment Sequence Group 3	Normal saline gargle	Treatment Sequence Group 3 = C -\> A -\> B Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
Treatment Sequence Group 1	1% Betadine® PVP-I based mouth wash and gargle,	Treatment Sequence Group 1 = A -\> B -\> C Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm).
Treatment Sequence Group 3	1% Betadine® PVP-I based mouth wash and gargle,	Treatment Sequence Group 3 = C -\> A -\> B Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)
Treatment Sequence Group 2	0.2% Chlor-Rinse™ Chlorhexidine based mouth wash	Treatment Sequence Group 2 = B -\> C -\> A Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle
Treatment Sequence Group 2	Normal saline gargle	Treatment Sequence Group 2 = B -\> C -\> A Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol) Treatment C = Normal saline gargle (lukewarm). Treatment A = 1% Betadine® PVP-I based mouth wash and gargle

Primary Outcome Measures

Name	Time	Method
Composition of oral microbiome - reduction of microflora	Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)	The change (amount and variety) of oral microflora species composition from baseline after the usage of a single dose of different antiseptic mouth washes using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins .
Composition of oral microbiome - maintenance of healthy microflora	Swab 1 - 0 Min, Swab 2 - 3 min (post treatment) and Swab 3 - 240 min (post treatment)	The change (amount and variety) of healthy oral microflora species composition from baseline after the usage of a single dose of different antiseptic mouth washes using next generation sequencing (NGS) and real-time PCR techniques at 3 mins and 240 mins.

Trial Locations

Locations (1)

National University of Singapore Hospital; 🇸🇬 Singapore, Singapore